News and Announcements
Cellmid Ltd – CEO Interview
- Published November 09, 2012 6:14PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Cellmid (ASX: CDY) develops innovative therapies and diagnostics for cancer, inflammation and heart attack. CDY has the largest global IP portfolio related to growth factor midkine (MK). Its most advanced program is for MK antibodies targeting cancer/inflammation. CDY is also developing MK protein to treat heart attack and other ischemia.
Executive Interviews
The Democratisation of Private Equity: How $500 Now Buys What Institutions Own
Private equity used to be something that happened over there. Big banks. Big institutions. Deals you read about in the AFR. Now it is entering everyday life. Your mum or dad who has had a business for 30 or 40 years is transitioning that business to private equity. Your favourite sporting team is being assisted […]
What is a Wholesale Investor in Australia? Complete 2026 Guide
What is a Wholesale Investor in Australia? A wholesale investor is an individual or entity that meets specific financial thresholds set out in the Corporations Act 2001 (Cth), qualifying them to access investment opportunities that are not available to general retail investors. These include private equity rounds, venture capital deals, pre-IPO placements, alternative funds, and […]
Why the 20-Year Hold Is the Secret to Australian Life Sciences Returns
Australia represents 0.3% of the world’s population. Yet it generates more than 3% of global research output. Cochlear implants. Wi-Fi. The HPV vaccine. These are not statistical anomalies. They are proof points of a structural advantage that Australia has failed to capitalise on. The country has a world-class research base. But it watches companies scale […]
Backed By Leading Investment Groups and Family Offices
